How should the R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen be administered?

How to Administer R-CHOP

R-CHOP should be administered as 6-8 cycles given every 21 days (R-CHOP-21), with rituximab 375 mg/m² on day 1, cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² (max 2 mg) all IV on day 1, and prednisone 100 mg/day orally on days 1-5. 1, 2

Dosing Schedule by Patient Population

Patients Aged 60-80 Years (Standard Population)

• 6-8 cycles of R-CHOP-21 is the current standard 1
• Each cycle administered every 21 days
• Total of 8 doses of rituximab
• R-CHOP-14 (every 14 days) showed no survival advantage over R-CHOP-21 and should not be used 1, 3, 4

Young Patients (Age <60)

Low-intermediate risk (aa-IPI = 1) or low risk with bulky disease:

• R-CHOP-21 × 6 cycles plus radiotherapy to bulky sites 1
• Alternative: R-ACVBP (intensified regimen) if radiotherapy omitted 1

High/high-intermediate risk (aa-IPI ≥ 2):

• 6-8 cycles of R-CHOP-21 with 8 doses of rituximab 1
• R-CHOP-14 failed to show benefit even in this subset 1
• Clinical trial enrollment should be prioritized

Patients >80 Years

• R-CHOP can be used in fit patients 1
• Comprehensive geriatric assessment recommended to guide treatment modifications 1

Infusion Administration Details

First Infusion Protocol 2

• Start at 50 mg/hr
• Increase by 50 mg/hr increments every 30 minutes if no infusion toxicity
• Maximum rate: 400 mg/hr

Subsequent Infusions 2

• Start at 100 mg/hr
• Increase by 100 mg/hr increments every 30 minutes
• Maximum rate: 400 mg/hr

Accelerated 90-Minute Infusion Option 2

Only for DLBCL patients in Cycle 2 and beyond if:

• No Grade 3-4 infusion reaction in Cycle 1
• Given with glucocorticoid-containing chemotherapy
• Contraindications: Significant cardiovascular disease OR circulating lymphocyte count ≥5,000/mm³

Administration: 20% of total dose over first 30 minutes, then 80% over next 60 minutes

Critical Safety Measures

Mandatory Premedication

• Premedicate before each infusion 2
• Glucocorticoids (methylprednisolone 100 mg IV or equivalent) 30 minutes prior to rituximab 1

Tumor Lysis Syndrome Prevention

For high tumor burden patients: 1

• Administer prednisone orally for several days as "prephase" treatment before starting R-CHOP
• This is a Level I, Grade A recommendation

Hematologic Toxicity Management

• Avoid dose reductions for hematological toxicity 1
• Use prophylactic G-CSF for:
  • Febrile neutropenia
  • Patients >60 years treated with curative intent
  • This is Level I, Grade A evidence 1

Hepatitis B Screening

• Screen all patients for HBV (HBsAg and anti-HBc) before initiating treatment 2

Monitoring Requirements

• CBC with differential and platelets prior to each cycle 2
• During R-CHOP + chemotherapy: CBC weekly to monthly, more frequently if cytopenias develop 2

Common Pitfalls to Avoid

1. Do not use R-CHOP-14: Multiple high-quality trials 3, 4 demonstrated no survival benefit with the dose-dense 14-day schedule compared to standard 21-day dosing, with increased toxicity (more transfusions, neutropenia)

2. Do not reduce doses for neutropenia: This is strongly discouraged by guidelines 1; instead, use G-CSF support

3. Do not skip tumor lysis prophylaxis: In high tumor burden cases, prephase prednisone is essential 1

4. Do not give rituximab as IV push or bolus: Must be given as infusion only 2

5. Do not use accelerated infusions in first cycle or in patients with cardiovascular disease 2

Number of Cycles

• Standard: 6-8 cycles depending on disease stage and risk 1
• Limited-stage, low-risk disease: 6 cycles may be sufficient
• Advanced-stage disease: typically 6-8 cycles
• If using R-CHOP-14: 6 cycles of CHOP with 8 cycles of rituximab 1